Fundamentos de sus aplicaciones | 26 MAR 24

Test del ADN fecal para la detección del cáncer colorrectal

El examen de ADN fecal es una estrategia no invasiva recomendada por varias sociedades profesionales médicas para la detección del cáncer colorrectal en personas de riesgo promedio.
Autor/a: John M. Carethers Annu. Rev.Med. 2020. 71:5969
INDICE:  1. Texto principal | 2. Referencias bibliográficas
Referencias bibliográficas

1. Siegel RL,Miller KD, Jemal A. 2019. Cancer statistics, 2019. CA Cancer J. Clin. 69:7–34

2. Nishihara R,Wu K, Lochhead P, et al. 2013. Long-term colorectal-cancer incidence and mortality after lower endoscopy.N. Engl. J. Med. 369:1095–105

3. Zauber A,Winawer SJ,O’Brien MJ, et al. 2012. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths.N. Engl. J. Med. 366:687–96

4. Shaukat A, Mongin SJ,GeisserMS, et al. 2013. Long-termmortality after screening for colorectal cancer. N. Engl. J. Med. 369:1106–14

5. Rex DK, Boland CR, Dominitz JA, et al. 2017. Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology 153:307–23

6. Carethers JM. 2015. Screening for colorectal cancer in African Americans: determinants and rationale for an earlier age to commence screening. Digest. Dis. Sci. 60:711–21

7. Ahlquist DA. 2015. Multi-target stool DNA test: a new high bar for noninvasive screening. Digest. Dis. Sci. 60:623–33

8. Lin JS, Webber EM, Beil TL, et al. 2012. Fecal DNA testing in screening for colorectal cancer in averagerisk adults: comparative effectiveness review. Executive summary no. 52. AHRQ Pub. No. 12-EHC022-1. Rockville, MD: Agency for Healthcare Research and Quality. Accessed June 1, 2019

9. Carethers JM. 2014. DNA testing and molecular screening for colon cancer. Clin. Gastroenterol. Hepatol. 12:377–8110. Grady WM, Carethers JM. 2008. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 135:1079–99

11. Carethers JM, Jung BH. 2015. Genetics and genetic biomarkers in sporadic colorectal cancer. Gastroenterology 149:1177–90

12. Cancer Genome Atlas Network. 2012. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330–37

13. Carethers JM. 2016. Hereditary, sporadic and metastatic colorectal cancers are commonly driven by specific spectrums of defective DNA mismatch repair components. Trans. Am. Clin. Climatol. Assoc. 127:81–97

14. Carethers JM. 2017. Microsatellite instability pathway and EMAST in colorectal cancer. Curr. Colorectal Cancer Rep. 13:73–80

15. Carethers JM, Fearon ER. 2015. Molecular subtyping of colorectal cancer: time to explore both intertumoral and intratumoral heterogeneity to evaluate patient outcome. Gastroenterology 148:10–13

16. Koi M, Garcia M, Choi C, et al. 2016. Microsatellite alterations with allelic loss on 9p24.2 signify les aggressive colorectal cancer metastasis. Gastroenterology 150:944–55

17. Coppede F, Lopomo A, Spisni R, Migliore L. 2014. Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer.World J. Gastroenterol. 20:943–56

18. Carethers JM. 2015. Biomarker-directed targeted therapy in colorectal cancer. J. Digest. Cancer Rep. 3:5–10

19. Klaassen CH, JeuninkMA, Prinsen CR, et al. 2003. Quantification of human DNA in feces as a diagnostic test for the presence of colorectal cancer. Clin. Chem. 49:1185–87

20. Anderson BW, Ahlquist DA. 2016. Molecular detection of gastrointestinal neoplasia. Gastroenterol. Clin. N. Am. 45:529–42

21. Sidransky D, Tokino T, Hamilton SR, et al. 1992. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 256:102–5

22. Zou H,Taylor WR, Harrington JJ, et al. 2009. High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay. Gastroenterology 136:459–70

23. Ahlquist DA, Sargent DJ, Loprinzi CL, et al. 2008. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann. Intern.Med. 149:441–50

24. Shen L, Toyota M, Kondo Y, et al. 2007. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc. Natl. Acad. Sci. USA 104:18654–59

25. Imperiale TF,Ransohoff DF, Itzkowitz SH, et al. 2004. FecalDNAversus fecal occult blood for colorectal cancer screening in an average-risk population.N. Engl. J. Med. 35:2704–14



Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024